Authors:
Zost, Seth J, Gilchuk, Pavlo, Chen, Rita, Case, James Brett, Reidy, Joseph X, Trivette, Andrew, Nargi, Rachel S, Sutton, Rachel E, Suryadevara, Naveen, Chen, Elaine C, Binshtein, Elad, Shrihari, Swathi, Ostrowski, Mario A, Chu, Helen Y, Didier, Jonat (...)
Zost, Seth J, Gilchuk, Pavlo, Chen, Rita, Case, James Brett, Reidy, Joseph X, Trivette, Andrew, Nargi, Rachel S, Sutton, Rachel E, Suryadevara, Naveen, Chen, Elaine C, Binshtein, Elad, Shrihari, Swathi, Ostrowski, Mario A, Chu, Helen Y, Didier, Jonathan E, MacRenaris, Keith W, Jones, Taylor, Day, Samuel, Myers, Luke, Lee, F. Eun-Hyung, Nguyen, Doan C, Sanz, Ignacio, Martinez, David R, Gralinski, Lisa, Baric, Ralph S, Thackray, Larissa, Diamond, Michael S, Carnahan Jr., Robert H, Crowe, James E
(Read More)
Abstract:
Antibodies are a principal determinant of immunity for most RNA viruses and have promise to reduce infection or disease during major epidemics. The novel coronavirus SARS-CoV-2 has caused a global pandemic with millions of infections and hundreds of thousands of deaths to date1,2. In response, we used a rapid antibody discovery platform to isolate hundreds of human monoclonal antibodies (mAbs) against the SARS-CoV-2 spike (S) protein. We stratify these mAbs into five major classes based on their reactivity to subdom (...)
Antibodies are a principal determinant of immunity for most RNA viruses and have promise to reduce infection or disease during major epidemics. The novel coronavirus SARS-CoV-2 has caused a global pandemic with millions of infections and hundreds of thousands of deaths to date1,2. In response, we used a rapid antibody discovery platform to isolate hundreds of human monoclonal antibodies (mAbs) against the SARS-CoV-2 spike (S) protein. We stratify these mAbs into five major classes based on their reactivity to subdomains of S protein as well as their cross-reactivity to SARS-CoV. Many of these mAbs inhibit infection of authentic SARS-CoV-2 virus, with most neutralizing mAbs recognizing the receptor-binding domain (RBD) of S. This work defines sites of vulnerability on SARS-CoV-2 S and demonstrates the speed and robustness of new antibody discovery methodologies.
(Read More)